FABIANI & COMPANY for OCERA THERAPEUTICS INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Termination | Apr 20, 2010 | — | Replaced |
| 1st Quarter - Termination Amendment (this page) | Sep 21, 2012 | — | Replaced |
| 1st Quarter - Termination Amendment | Jan 24, 2013 | — | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Funding for biopharmaceutical product development to address nuclear warfare threats.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA DUPREE | — |
| ERIN FRY | — |
| WENDY SHELTON | — |
Defense DEF
Funding for biopharmaceutical product development with the Department of Defense to treat long term health impact of chronic substance abuse.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA DUPREE | — |
| ERIN FRY | — |
| WENDY SHELTON | — |
Budget/Appropriations BUD
Fiscal Year 2010 Defense Appropriations Act. Funding for biopharmaceutical product trials for treatment to address long term health impact of substance abuse in military populations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA DUPREE | — |
| WENDY SHELTON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.